PMH12 Risk of Relapse and Hospitalization in the 2-Year Open-Label Treatment of Outpatients with Schizophrenia Randomized to Olanzapine Long-Acting Injection or Oral Olanzapine
Abstract
Authors
D. Novick H. Ascher-Svanum J. Bertsch H. Detke D. Mcdonnell M. Witte J. Haro